90 results about "K pneumoniae" patented technology

This invention discloses nucleic acid aptamers that specifically bind to the OmpK36 protein and their applications. Through analysis and screening, aptamers APT-1 and APT-2 that specifically bind to the OmpK36 protein were obtained. Nucleic acid aptamer APT-1 can specifically bind to outer membrane polypeptides, while nucleic acid aptamer APT-2 can specifically bind to polypeptides specific to Klebsiella pneumoniae. Both can bind to the OmpK36 protein to form a complex structure, which can be used for the specific detection of Klebsiella pneumoniae, providing convenience for clinical detection, diagnosis and treatment, and exclusion detection of specific pathogens in SPF animals.

The invention relates to a binding protein B capable of binding with klebsiella pneumoniae and application of the binding protein B, and belongs to the technical field of molecular biology and protein engineering. The binding protein B provided by the invention can be specifically bound with an extramembrane part of a specific protein P24017. OMPAKLEPN of klebsiella pneumoniae, and experiments such as bimolecular fluorescence complementation and flow cytometry prove that the binding protein B has good recognition and stable binding capacity on the klebsiella pneumoniae, can be used for identifying and screening the klebsiella pneumoniae, and has good application prospects. And a key tool is provided for targeted drug development aiming at the bacterium.

The invention provides a lung-kidney interaction simulation system based on an organ chip, and the system comprises a lung chip module which is used for simulating a qi-blood barrier structure of a lung, and the lung chip module is inoculated with human alveolar epithelial cells and human lung microvascular endothelial cells; the kidney chip module is used for simulating a capillary lumen of a kidney tubule and a kidney tubule lumen structure, and human kidney tubule epithelial cells and human umbilical vein endothelial cells are inoculated on the kidney chip module; the connecting channel is used for communicating the lung chip module with the kidney chip module and allowing the culture medium to flow between the lung chip module and the kidney chip module; and wherein a klebsiella pneumoniae liquid for causing lung injury is applied to the upper layer of the lung chip module. The invention provides a novel simulation system for the research of lung-kidney interaction, and solves the limitation of animal experiments.

The application belongs to the technical field of medicine and pharmacy, and particularly relates to application of vanillin in preparation of a Klebsiella pneumoniae capsule inhibitor. The application relates to application of vanillin in preparation of an inhibitor for inhibiting formation, adhesion or function of a Klebsiella pneumoniae capsule, and related antibacterial or anti-infection products, wherein the vanillin reduces pathogenicity of Klebsiella pneumoniae by inhibiting capsule synthesis. It is disclosed that the vanillin can effectively inhibit formation of a Klebsiella pneumoniae capsule and reduce viscosity of bacteria, and can effectively treat mice infected with Klebsiella pneumoniae.

The invention relates to a primer and probe combination for simultaneously detecting urinary tract klebsiella pneumoniae, escherichia coli and drug-resistant genes through nested PCR (Polymerase Chain Reaction) and a kit of the primer and probe combination, which are characterized in that a phoE target gene is selected for primer and probe design to ensure that cross amplification of related bacteria is not caused, so that the detection specificity requirement of actual klebsiella pneumoniae is met; the Klebsiella pneumoniae and the escherichia coli can be identified at the same time, the source of the drug-resistant gene KPC can be judged, and the method is very important for clinical precise diagnosis and treatment.

The application provides a drug delivery system for targeted treatment of inflammatory diseases and a preparation method and application thereof, and belongs to the technical field of biological drugs. The drug delivery system for targeted treatment of inflammatory diseases is M2 type macrophages phagocytizing drug-loaded nanoparticles, wherein the drug-loaded nanoparticles comprise a biodegradable high molecular material for coating drugs. The drug delivery system prepared by the application realizes lung targeted delivery through the natural inflammatory chemotaxis characteristics of M2 type macrophages, and in combination with the drug slow-release effect of the drug-loaded nanoparticles, the drug targeting and availability are significantly improved, so that the drug efficacy is improved, the biological safety is good, and a new effective means is provided for the clinical treatment of various inflammatory diseases including carbapenem-resistant Klebsiella pneumoniae (CRKP) pneumonia.

FIELD: molecular biology.SUBSTANCE: method for predicting a high risk of adverse outcome in a patient with purulent lung disease (PLD) infected with gram-negative bacteria of the Klebsiella pneumoniae species is described. The method involves isolating DNA from peripheral venous blood and determining variants of the AQP4 rs1058424 gene. When the AQP4 rs1058424 AA genotype is detected in a patient with PLD and the presence of signs of Klebsiella pneumoniae infection, a high risk of death is determined.EFFECT: based on the determination of the AQP4 rs1058424 genotype for patients with PLD and identified gram-negative bacteria, it becomes possible to fairly early divide hospitalized patients with purulent infection into high-risk and low-risk groups for a fatal outcome.1 cl, 4 ex

The application belongs to the technical field of non-antibiotic compounds as bacteriostatic agents, and discloses an application of a known non-antibiotic compound, cladrabine, in inhibiting the growth of multi-drug resistant Klebsiella pneumoniae. The application finds that cladrabine can inhibit the growth of multi-drug resistant Klebsiella pneumoniae, and the minimum bacteriostatic concentration reaches 64 mg / L. Further exploration of the bacteriostatic mechanism finds that after exposure to cladrabine, the permeability of the bacterial cell membrane is enhanced, and the macromolecular substances (nucleic acids and proteins) in the cell are excreted, causing the integrity of the bacterial cell membrane to be destroyed, and further causing the death of Klebsiella pneumoniae. The application proposes that cladrabine can destroy the cell membrane of bacteria, change the permeability of the cell membrane, has a good inhibitory effect on multi-drug resistant Klebsiella pneumoniae, and can be further applied to the preparation of related drugs.

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.

The present application relates to a kind of binding protein B combined with klebsiella pneumoniae and its application, belong to molecular biology and protein engineering technical field.The binding protein B provided by the present application can specifically bind the membrane outer part of the unique protein P24017 of klebsiella pneumoniae OMPA_KLEPN, and its good recognition and stable binding capacity for klebsiella pneumoniae are verified by double-molecule fluorescence complementation, flow cytometry and other experiments, can be used for the identification and screening of klebsiella pneumoniae, provides key tool for the targeted drug development for the bacteria.

The invention provides a preparation method and application of alpinia oxyphylla leaf essential oil, and relates to the field of natural plant extracts. The alpinia oxyphylla leaf essential oil is applied to preparation of a bacteriostatic agent for inhibiting bacteria or / and fungi, and the bacteria comprise one or more of klebsiella pneumoniae, salmonella enterobacter and shigella flexneri. The fungi comprise one or more of candida tropicalis and malassezia furfur; the preparation method of the alpinia oxyphylla leaf essential oil comprises the following steps that alpinia oxyphylla leaves are taken, dried and smashed, the smashed alpinia oxyphylla leaves are placed in water to be soaked, the material-liquid mass ratio is 1: (15-17), and the soaking time is 0.8-1.2 h; after soaking, distillation is carried out, the distillation time is 4.5-5.5 h, and the distillation temperature is 170-200 DEG C; and after distillation is finished, collecting upper oily liquid to obtain the alpinia oxyphylla leaf essential oil. The prepared alpinia oxyphylla leaf essential oil has broad-spectrum antibacterial and bactericidal effects, and the antibacterial and bactericidal effects are good.

The application belongs to the field of genetic engineering and medical engineering, and discloses virK Application of gene in regulation of Klebsiella pneumoniae virulence. The application finds that the expression level of the gene is significantly increased in polymyxin-resistant mutant strains through transcriptome analysis, virK Further research shows that the expression of the gene is regulated by the PhoP / PhoQ two-component regulatory system. The application constructs virK Gene deletion mutant strains and complementary strains, and compares the virulence difference of the strains in an animal infection model, finds that virK The virulence of the deletion strain is significantly reduced, and the complementary strain can restore the virulence phenotype, indicating that virK The gene plays an important role in the regulation of Klebsiella pneumoniae virulence. The application first finds that PhoP can regulate virK Gene expression, and affects the virulence phenotype of Klebsiella pneumoniae through the regulation pathway, thereby revealing a new virulence regulation mechanism, and providing a theoretical basis for subsequent targeted intervention.

The application discloses a method for identifying Klebsiella pneumoniae gene circadian rhythm expression by using a bioluminescence reporting system. The application constructs a recombinant bioluminescence Klebsiella pneumoniae driven by a metabolic gene malate:quinone oxidoreductase mqo promoter (Pmqo), and directly observes the change rule of bacterial gene expression under entrainment and free-running conditions of temperature cycle by monitoring the luminescence characteristics. The luxCDABE gene operon comprises genes for coding luciferase and substrate synthesis enzyme, wherein luxA and luxB code for heterodimer luciferase, luxC, luxD and luxE synthesize aldehyde as a substrate for the luciferase luminescence reaction. The luciferase catalyzes the oxidation of aldehyde to generate visible blue-green light with a wavelength of 450-490 nm. The Lux bioluminescence reporting system has the advantages of not needing to add an exogenous substrate and not affecting the normal physiological functions of the host, and can be applied to the identification of Klebsiella pneumoniae gene circadian rhythm expression.

The embodiment of the application relates to a primer group, application and detection method of a fluorescent quantitative PCR for identifying high-toxicity Klebsiella pneumoniae, wherein the primer group comprises a primer pair of one or more of SEQ ID NO: 1 to SEQ ID NO: 26, and the primer group can improve the identification accuracy of the high-toxicity Klebsiella pneumoniae.

This application provides a method for generating emergency treatment recommendations based on Klebsiella pneumoniae classification prediction, including: acquiring Klebsiella pneumoniae case data for a set time period; identifying homologous Klebsiella pneumoniae case data based on mass spectrometry data in the Klebsiella pneumoniae case data, and integrating the homologous Klebsiella pneumoniae case data to obtain Klebsiella pneumoniae case data groups; determining the feature vector of each Klebsiella pneumoniae case data based on the Klebsiella pneumoniae case data group; inputting the feature vector of each Klebsiella pneumoniae case data into a Klebsiella pneumoniae classification model to determine the classification corresponding to each Klebsiella pneumoniae case data; and generating emergency treatment recommendations based on the classification corresponding to each Klebsiella pneumoniae case data. This solution can provide emergency recommendations during the transition period, so as to promptly attract the attention of medical staff and take appropriate measures.

The invention relates to a Klebsiella pneumoniae bacteriophage vBKpnSYPH3 carrying a KPC-2 type enzyme mutant and application thereof, and belongs to the technical field of microorganisms, the bacteriophage is preserved in the China Center for Type Culture Collection on May 28, 2025, the preservation number is CCTCC No.20251208, and the preservation number is CCTCC No.20251208. The Klebsiella pneumoniae bacteriophage vBKpnSYPH3 can be used for preparing the Klebsiella pneumoniae bacteriophage vBKpnSYPH3. The bacteriophage can effectively split strains which are evolved from original strains of blaKPC-2 genes and carry mutant genes such as blaKPC-33 and the like, the bacteriophage has unique sensitivity to specific mutants of KPC enzyme, and a brand-new tool and thought are provided for solving treatment blind areas generated in the drug-resistant evolution process of bacteria.

The invention relates to the technical field of water treatment materials, and discloses a nano-catalytic antibacterial filter material for a direct water dispenser, which comprises the following components in percentage by mass: 8-20% of broad-spectrum nano-antibacterial component, 55-85% of base material, 4-10% of binder, 2-5% of dispersant and 2-6% of assistant, the broad-spectrum nano antibacterial component is Ag-TiO / ZnO-CuO quaternary composite nanoparticles, and the mass ratio of Ag to TiO to ZnO to CuO is 1: (2-4): (1-3): (0.5-1.5). According to the nano catalytic antibacterial filter material and the preparation method thereof, the inhibition and killing rates on gram-negative bacteria (escherichia coli, pseudomonas aeruginosa and klebsiella pneumoniae), gram-positive bacteria (staphylococcus aureus, bacillus subtilis and methicillin-resistant staphylococcus aureus) and fungi (candida albicans and aspergillus niger) are all greater than or equal to 99.9%.

The invention belongs to the technical field of bioengineering, and particularly relates to a phage cocktail and application thereof. The bacteriophage cocktail comprises five bacteriophages PGPA20, PGPA60, PAB26, Lkpp-25 and Lkpp-36 which are separated from the natural world, and the bacteriophage cocktail has relatively strong bactericidal activity on pseudomonas aeruginosa, acinetobacter baumannii and K1 / K2 type klebsiella pneumoniae, and has specificity on the pseudomonas aeruginosa, the acinetobacter baumannii and the K1 / K2 type klebsiella pneumoniae; the bacteriophage can be compounded with other substances for use, and a safe and non-toxic bacteriophage killing product is provided for in-vivo and in-vitro infection treatment of pseudomonas aeruginosa, acinetobacter baumannii and K1 / K2 type klebsiella pneumoniae and disinfection and purification of pseudomonas aeruginosa, acinetobacter baumannii and K1 / K2 type klebsiella pneumoniae in the breeding industry and other environments.

The application discloses K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies, hybridoma cell strains thereof and application of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies, sequence information of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies is shown as SEQ NO:1-SEQ NO:56, preservation numbers of the hybridoma cell strains are CCTCC:C2023365, CCTCC:C2023366, CCTCC:C2023367, CCTCC:C2024340, CCTCC:C2024341, CCTCC:C2024342 and CCTCC:C2024343 respectively, the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies provided by the application can be specifically combined with capsular polysaccharide of Klebsiella, are favorable for typing of Klebsiella pneumoniae in clinic, and can prove excellent effects of the K64 type Klebsiella pneumoniae capsular polysaccharide monoclonal antibodies in preventing and treating infection of Klebsiella pneumoniae in in-vivo and in-vitro tests, and the application provides a way for solving problems of Klebsiella pneumoniae infection and multiple drug resistance, has remarkable significance for preventing, diagnosing and treating Klebsiella pneumoniae infection, and has important value for developing a new generation of Klebsiella pneumoniae drugs.

The invention discloses application of chlorogenic acid combined with sivelestat sodium in prevention and treatment of infectious diseases. Through animal in-vivo experiments, the protective effect of chlorogenic acid (CGA) and sivelestat sodium (SIV) on mouse lethality caused by klebsiella pneumoniae (Kpn) infection is verified in a constructed model of sepsis caused by klebsiella pneumoniae infection, the survival rate of infected mice can be increased by combining chlorogenic acid (CGA) and sivelestat sodium (SIV), the weight loss of the mice caused by infection can be resisted, and the curative effect of the sivelestat sodium (SIV) on the mice caused by klebsiella pneumoniae (Kpn) can be improved. Experiments prove that continuous intraperitoneal injection of chlorogenic acid does not cause significant change of hemogram-related indexes, indicating that chlorogenic acid has good safety. According to the scheme of combining the chlorogenic acid with the sivelestat sodium, through the advantages of precise targeted anti-inflammation, two-way immune regulation, anti-infection and immune synergy and the like, the defects of an existing immune regulation technology for bacterial sepsis are comprehensively overcome, and a new optimization direction is provided for clinical treatment.

The invention discloses a carbapenem drug resistance gene detection primer group based on multiple PCR-time-of-flight mass spectrometry, a detection kit and a kit using method, and through a large number of screening and verification experiments, a multiple primer group suitable for time-of-flight mass spectrometry detection is obtained. Therefore, the multi-PCR-time-of-flight mass spectrometry detection of the multi-drug-resistant genes of carbapenem-resistant enterobacteriaceae bacteria becomes possible. The detection kit prepared by adopting the primer group can be used for simultaneously detecting and identifying 10 common carbapenem drug-resistant genes, including klebsiella pneumoniae KPC gene, NDM gene, IMP gene, VIM gene and OXA gene, acinetobacter baumannii OXA gene, NDM gene, Escherichia coli OXA gene, IMP gene and serratia marcescens VIM gene. Meanwhile, the kit is high in sensitivity and specificity, dozens of times of detection can be carried out in the same batch, so that the detection efficiency is greatly improved, and the kit is suitable for rapid screening and genetic typing of carbapenem drug-resistant bacteria in clinical samples.

The invention belongs to the technical field of biological medicines, and discloses a cyclized antibacterial peptide CycP-1 targeting multiple drug-resistant klebsiella pneumoniae, and a composition and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1, cysteine residues at the first site and the 24th site in a molecule of the antibacterial peptide form a disulfide bond, and the antibacterial peptide is in cyclization conformation and shows good in-vitro protease stability. Experiments show that the antibacterial peptide has a remarkable inhibiting effect on multi-drug-resistant and pan-drug-resistant klebsiella pneumoniae, and when the antibacterial peptide is combined with antibiotics, the antibacterial effect can be enhanced, drug resistance can be reversed or reduced, and generation of drug resistance can be delayed. A mouse pneumonia model in-vivo experiment further proves that after oral administration of the antibacterial peptide, the lung tissue bacterial load of a pan-drug resistant klebsiella pneumonia infected mouse can be remarkably reduced, lung pathological injury is relieved, the survival rate of the infected mouse is remarkably increased, and the effect is better when the antibacterial peptide is combined with polymyxin B.

The invention belongs to the technical field of biological medicine, and discloses a bacteriophage depolymerases Depo17 and a preparation method and application thereof, the amino acid sequence of the bacteriophage depolymerases Depo17 is shown as SEQ ID No: 2, the bacteriophage depolymerases Depo17 can be used for preparing a preparation for enhancing the phagocytosis of macrophages on klebsiella pneumoniae, and a new strategy is provided for anti-infection treatment.

The invention discloses application of cinnamic acid in preparation of a klebsiella pneumoniae capsular inhibitor and belongs to the technical field of biological medicine, the CAS login number of the cinnamic acid is 140-10-3, the molecular formula of the cinnamic acid is C9H8O2, the molecular weight of the cinnamic acid is 148.16, and the cinnamic acid has an inhibiting effect on klebsiella pneumoniae capsular synthesis. The invention solves the problem that the application of cinnamic acid in preparation of klebsiella pneumoniae capsule inhibitors is not researched and reported at present. Through uronic acid determination, Anthony's capsular staining, a growth curve test, cytotoxicity, a klebsiella pneumonia infection greater wax moth protection test and other analysis, it is proved that cinnamic acid can reduce the pathogenicity of klebsiella pneumonia by inhibiting capsular synthesis, and then the effective anti-infection effect is achieved; a novel treatment means is provided for clinical drug-resistant klebsiella pneumoniae infection, and a lead compound with definite functions is provided for subsequent research.

The present application relates to a Klebsiella pneumoniae bacteriophage, a bacteriophage composition thereof and application thereof, and belongs to the field of microorganisms. The present application provides a lytic bacteriophage Kp_WF01 infecting Klebsiella pneumoniae, and biological property research, morphological observation and whole-genome phylogenetic analysis are performed on the bacteriophage, and it is determined that the bacteriophage Kp_WF01 is a new species of Caudoviricetes Class Autographivirales Order Autotranscriptaviridae Family Przondovirus Genus. The in-vivo treatment effect and safety of the bacteriophage Kp_WF01 are evaluated by using a mouse model infected with CRKP, and the results show that the bacteriophage Kp_WF01 can rescue the CRKP-infected mouse, can be used as an effective therapeutic preparation against CRKP infection, and the treatment effect of the bacteriophage Kp_WF01 is better than that of imipenem.

The invention relates to a bovine umbilical cord cell, a preparation method thereof, a conditioned medium and an antibacterial method thereof. The bovine umbilical cord cell is obtained through a specific enzyme digestion and culture system, is fusiform and has high activity; the conditioned medium is obtained by culturing bovine umbilical cord cells in MEM-alpha for 24 hours, centrifuging, taking supernate and filtering. The invention has the beneficial effects that the cell and the conditioned medium prepared from the cell show extremely strong bacteriostatic activity on staphylococcus aureus and klebsiella pneumoniae, and the bacteriostatic rate can reach 95% or above; the antibacterial effect can be partially reversed by exogenous iron; the invention provides important cell resources and material basis for developing novel, efficient and cell-free antibacterial biological products, and has wide application prospect in the field of anti-infection treatment.

The invention discloses a klebsiella pneumoniae bacteriophage vBKpnMpha0172 and application thereof, and belongs to the technical field of microorganisms. The Klebsiella pneumoniae phage vBKpnMpha0172 is preserved in the Guangdong Microbiological Culture Collection Center on November 13, 2025, the preservation number is GDMCC NO: 67291-B1, and the preservation address is Institute of Microbiology, Academy of Sciences, Guangdong Province. The bacteriophage has excellent temperature and pH environment tolerance, the optimal infection complex number is as low as 0.00001, the initial use dosage of the bacteriophage is greatly reduced, high adsorption rate and rapid outbreak proliferation characteristics are combined, efficient lysis pressure on host bacteria can be formed in a short time, and the application range of the bacteriophage is widened. The method has a good application prospect in the industries of food preservation, environment disinfection, livestock breeding, poultry breeding, aquaculture, water treatment, biomedical treatment and the like.

The present application relates to the technical field of computer information processing, and particularly relates to a klebsiella pneumoniae drug resistance detection method, system, device and medium, the method comprising: acquiring and processing original mass spectrum data of a to-be-tested strain, determining topological persistence to screen characteristic peaks, and constructing an ordered characteristic sequence; generating a view pair using data enhancement, and mapping it into a position encoding and intensity embedding tensor, combining embedding labels to construct an input sequence; inputting the input sequence into an interpretable contrastive learning network, using an attention mechanism and contrastive learning to optimize representation consistency and update a feature extractor; finally, freezing the extractor parameters and connecting a classification head, adjusting using labeled samples to realize discrimination of collaborative representation. Thus, by combining topological persistence feature extraction and an interpretable contrastive learning network, using an attention mechanism and aggregation logic, the present application eliminates the black box property in the decision-making process, and realizes high-precision drug resistance detection with clinical reliability.

The invention belongs to the technical field of biological medicine detection, and discloses a reinforcing agent of a Cas12a fluorescence detection system, preparation and application in a detection kit. The enhancer is a circular amplicon, and a non-amplified Cas12a system is used for high-sensitivity nucleic acid detection of klebsiella pneumoniae for the first time. Aiming at the design of a Klebsiella pneumoniae Cas12a system, an annular nano structure is synthesized and is used for enhancing the Cas12a detection system. According to the preparation method of the reinforcing agent, the cyclic chain 1 is directly synthesized and then is mixed with chain c in an equimolar manner, so that the operation is simple and convenient, and a complicated chemical cyclization step is not needed. According to the CRISPR / Cas12a klebsiella pneumoniae detection kit, through the cascade signal amplification effect of the enhancer, high-sensitivity and high-specificity detection without pre-amplification is realized.

The invention belongs to the technical field of bioengineering, and particularly relates to application of an inhibitor of phage depolymerases of targeted KN1 serotype klebsiella pneumoniae. The inhibitor is 1, 2, 3, 6-tetragalloylglucose and 1, 2, 3, 4, 6-pentagalloylglucose, and the inhibitor is one or more of 1, 2, 3, 6-tetragalloylglucose and 1, 2, 3, 4, 6-pentagalloylglucose. The inhibitor provided by the invention can be combined with KN1 serotype klebsiella pneumoniae depolymerases (Dp42, KN1dep) to inhibit the degradation activity of the KN1 serotype klebsiella pneumoniae depolymerases on klebsiella pneumoniae capsular polysaccharide (CPS), so that the depolymerases mediated bacterial infection related biological process is regulated and controlled; the method can be applied to research and development of drugs related to regulation and control of the activity of the depolymerases, research of metabolic mechanisms of bacterial capsular polysaccharides and other scenes.